An experimental Boehringer Ingelheim drug achieved “unprecedented” benefits in patients with an advanced form of lung cancer ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Triple negative breast cancer is aggressive and hard to treat. It also disproportionately affects Black women. A University ...

The drug receives conditional marketing authorization by the CHMP for the treatment of HER2-positive biliary tract cancer.

It targets cancers linked to a protein called HER2. This approval is an exciting development because it could save lives and offer hope to patients who may have run out of treatment options. The drug ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

The trial demonstrated that zongertinib, a HER2-targeted tyrosine kinase inhibitor, elicited durable responses in patients with advanced, previously treated HER2-mutated non–small cell lung cancer .

The findings published Monday analyzed data from 2001 through 2022. However, incidence rates among women have been rising. Separately, a survey shows women are reluctant to have cancer screening ...